Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Exxon Mobil Corporation — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B), while Exxon Mobil Corporation trades at $159.7 (market cap $634.34B). The key difference: Exxon Mobil Corporation is far larger — about 4.8× Vertex Pharmaceuticals Incorporated's market cap, and Exxon Mobil Corporation pays a 2.69% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | XOM | |
|---|---|---|
Market Cap | $132.79B | $634.34B |
Sector | Health | Energy |
52-Week High | $529.65 | $171.52 |
52-Week Low | $376.62 | $106.13 |
Enterprise Value | $126.92B | $673.57B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
ExxonMobil (XOM) trades at $159.80, up 4.49% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q1 2026 but missing in Q2, while revenue and net income have trended lower since 2022. The company maintains robust cash flow from operations and a solid balance sheet with low debt levels, supporting consistent dividends.
Outlook remains positive due to high oil price forecasts and Permian Basin growth, but risks include declining profitability margins and geopolitical volatility. The stock offers value near the consensus price target of $163.71, with institutional sentiment leaning bullish amid energy sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
